Primary cancer of the fallopian tube: Report of 26 patients

Barbara Jereczek, Jacek Jassem, Anna Kobierska

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. Due to rarity of fallopian tube cancer most series on this tumor are small and many problems have remained unsolved. The aim of this report is to review our experience with this neoplasm and to compare it with previously published data. Methods. Retrospective study of 26 patients with fallopian tube cancer treated in one institution between 1974 and 1994. All patients underwent primary surgical treatment and 18 received adjuvant therapy including pelvic irradiation in 14 cases and chemotherapy in four. Results. Relapse occurred in 18 out of 25 followed up patients. Upper abdominal component of relapse was encountered in 12 patients (67%), pelvic component - in eight (44%) and extraperitoneal component - in six (33%). Pelvic relapse occurred in two out of 13 followed up patients treated with postoperative irradiation and in six out of 12 who did not receive postoperative radiotherapy. Survival ranged from 6 to 218+months (median 23 months). Five-year actual survival was 33%. There were no 2-year survivors in patients presenting with stage II-IV disease. No correlation was found between tumor grade and survival. Conclusions. Fallopian tube cancer is a treatable disease but cure can be only achieved in patients with early tumor. Postoperative radiotherapy may result in better local control but does not preclude extrapelvic dissemination, therefore adjuvant chemotherapy should be considered in high risk patients. Registration of all new cases as well as prospective multicenter studies are warranted to establish optimal management.

Original languageEnglish
Pages (from-to)281-286
Number of pages6
JournalActa Obstetricia et Gynecologica Scandinavica
Volume75
Issue number3
Publication statusPublished - 1996

Fingerprint

Fallopian Tube Neoplasms
Recurrence
Survival
Neoplasms
Radiotherapy
Adjuvant Chemotherapy
Multicenter Studies
Survivors
Retrospective Studies
Prospective Studies
Drug Therapy

Keywords

  • Fallopian tube cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Primary cancer of the fallopian tube : Report of 26 patients. / Jereczek, Barbara; Jassem, Jacek; Kobierska, Anna.

In: Acta Obstetricia et Gynecologica Scandinavica, Vol. 75, No. 3, 1996, p. 281-286.

Research output: Contribution to journalArticle

@article{3e400fbcded9492ca115507adb250853,
title = "Primary cancer of the fallopian tube: Report of 26 patients",
abstract = "Background. Due to rarity of fallopian tube cancer most series on this tumor are small and many problems have remained unsolved. The aim of this report is to review our experience with this neoplasm and to compare it with previously published data. Methods. Retrospective study of 26 patients with fallopian tube cancer treated in one institution between 1974 and 1994. All patients underwent primary surgical treatment and 18 received adjuvant therapy including pelvic irradiation in 14 cases and chemotherapy in four. Results. Relapse occurred in 18 out of 25 followed up patients. Upper abdominal component of relapse was encountered in 12 patients (67{\%}), pelvic component - in eight (44{\%}) and extraperitoneal component - in six (33{\%}). Pelvic relapse occurred in two out of 13 followed up patients treated with postoperative irradiation and in six out of 12 who did not receive postoperative radiotherapy. Survival ranged from 6 to 218+months (median 23 months). Five-year actual survival was 33{\%}. There were no 2-year survivors in patients presenting with stage II-IV disease. No correlation was found between tumor grade and survival. Conclusions. Fallopian tube cancer is a treatable disease but cure can be only achieved in patients with early tumor. Postoperative radiotherapy may result in better local control but does not preclude extrapelvic dissemination, therefore adjuvant chemotherapy should be considered in high risk patients. Registration of all new cases as well as prospective multicenter studies are warranted to establish optimal management.",
keywords = "Fallopian tube cancer",
author = "Barbara Jereczek and Jacek Jassem and Anna Kobierska",
year = "1996",
language = "English",
volume = "75",
pages = "281--286",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Primary cancer of the fallopian tube

T2 - Report of 26 patients

AU - Jereczek, Barbara

AU - Jassem, Jacek

AU - Kobierska, Anna

PY - 1996

Y1 - 1996

N2 - Background. Due to rarity of fallopian tube cancer most series on this tumor are small and many problems have remained unsolved. The aim of this report is to review our experience with this neoplasm and to compare it with previously published data. Methods. Retrospective study of 26 patients with fallopian tube cancer treated in one institution between 1974 and 1994. All patients underwent primary surgical treatment and 18 received adjuvant therapy including pelvic irradiation in 14 cases and chemotherapy in four. Results. Relapse occurred in 18 out of 25 followed up patients. Upper abdominal component of relapse was encountered in 12 patients (67%), pelvic component - in eight (44%) and extraperitoneal component - in six (33%). Pelvic relapse occurred in two out of 13 followed up patients treated with postoperative irradiation and in six out of 12 who did not receive postoperative radiotherapy. Survival ranged from 6 to 218+months (median 23 months). Five-year actual survival was 33%. There were no 2-year survivors in patients presenting with stage II-IV disease. No correlation was found between tumor grade and survival. Conclusions. Fallopian tube cancer is a treatable disease but cure can be only achieved in patients with early tumor. Postoperative radiotherapy may result in better local control but does not preclude extrapelvic dissemination, therefore adjuvant chemotherapy should be considered in high risk patients. Registration of all new cases as well as prospective multicenter studies are warranted to establish optimal management.

AB - Background. Due to rarity of fallopian tube cancer most series on this tumor are small and many problems have remained unsolved. The aim of this report is to review our experience with this neoplasm and to compare it with previously published data. Methods. Retrospective study of 26 patients with fallopian tube cancer treated in one institution between 1974 and 1994. All patients underwent primary surgical treatment and 18 received adjuvant therapy including pelvic irradiation in 14 cases and chemotherapy in four. Results. Relapse occurred in 18 out of 25 followed up patients. Upper abdominal component of relapse was encountered in 12 patients (67%), pelvic component - in eight (44%) and extraperitoneal component - in six (33%). Pelvic relapse occurred in two out of 13 followed up patients treated with postoperative irradiation and in six out of 12 who did not receive postoperative radiotherapy. Survival ranged from 6 to 218+months (median 23 months). Five-year actual survival was 33%. There were no 2-year survivors in patients presenting with stage II-IV disease. No correlation was found between tumor grade and survival. Conclusions. Fallopian tube cancer is a treatable disease but cure can be only achieved in patients with early tumor. Postoperative radiotherapy may result in better local control but does not preclude extrapelvic dissemination, therefore adjuvant chemotherapy should be considered in high risk patients. Registration of all new cases as well as prospective multicenter studies are warranted to establish optimal management.

KW - Fallopian tube cancer

UR - http://www.scopus.com/inward/record.url?scp=0029962920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029962920&partnerID=8YFLogxK

M3 - Article

C2 - 8607344

AN - SCOPUS:0029962920

VL - 75

SP - 281

EP - 286

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 3

ER -